AAMU
BBIO icon

Amundi Asset Management US’s BridgeBio Pharma BBIO Stock Holding History

Amundi Asset Management US’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$387K Sell
6,275
-2,725
-30% -$178K ﹤0.01% 1360
2020
Q4 		$640K Hold
9,000
– – ﹤0.01% 1258
2020
Q3 		$338K Buy
+9,000
New +$283K ﹤0.01% 1308
2019
Q3 		– Sell
-500
Closed -$13K – 1630
2019
Q2 		$13K Buy
+500
New +$13.6K ﹤0.01% 1616

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SUT
SC US (TTGP) Menlo Park, California $9.25B AUM 20.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Amundi Asset Management US's BBIO Position: Q1 2021 in Review

Amundi Asset Management US reduced its BridgeBio Pharma (BBIO) stake by 30% in Q1 2021, selling an estimated $178K and leaving 6,275 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #1360.

Amundi Asset Management US first reported a position in BBIO in Q2 2019 and has held it in 4 quarters since. The position peaked at $640K in Q4 2020. 198 funds tracked by Wall St. Rank hold BBIO as of Q1 2021.

  • Amundi Asset Management US held 6,275 shares of BridgeBio Pharma worth $387K as of Q1 2021.
  • Amundi Asset Management US sold 2,725 BridgeBio Pharma shares in Q1 2021, an estimated $178K.
  • BridgeBio Pharma made up ﹤0.01% of Amundi Asset Management US's portfolio in Q1 2021, its #1360 holding.
  • Amundi Asset Management US first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 4 quarters since.
  • Amundi Asset Management US's BridgeBio Pharma position peaked at $640K in Q4 2020.
  • 198 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2021.

Based on Amundi Asset Management US's 13F filing for Q1 2021, filed 17 May 2021.